By joining forces, the twelve member hospitals of the Group ensure that the best practices based on the latest knowledge in breast cancer are shared within the medical community of Quebec.
The Group provides them access to a vast network of hospitals and investigating physicians, as well as a larger pool of potentially eligible patients for their studies. This significantly increases the number of research protocols available to individuals with breast cancer. Both patients and sponsors benefit from the Group’s appeal, which aims to be a catalyst for clinical research in breast cancer in Quebec.
Whether it’s in the selection of member hospitals, the choice of research protocols to be conducted by the consortium, or the sharing of best practices, the patient’s interest is prioritized. Because our consortium ultimately serves its members and those affected, our team views its work as a privilege and a true opportunity to make a difference, one patient at a time.
The work accomplished and the involvement of all our collaborators within the member hospitals of the Group are integral to our success. The advances made together have a tangible and quantifiable impact, particularly in terms of participation rates of hospitals and patients in clinical studies.
The Group has also standardized clinical research practices across all its members. This harmonization allows for greater efficiency in their operations, whether it’s in the initiation of studies (providing patients quicker access to trials), communication, or quality control.
It leads the Group and is composed of members of the senior management from some member hospitals, as well as the founding couple.
This committee consists of globally recognized researchers who have been conducting research protocols for many years and wish to increase accessibility for individuals with breast cancer to these studies. Each member of the Group is represented on the SC, along with a representative from radiation oncology and a breast cancer specialist with expertise complementary to the clinical members of the scientific committee.
The SC sets the agenda, working methods, collaboration rules, performance indicators, and oversees the selection of research protocols conducted within the consortium. It also plays an advisory role in the implementation of the Programme Accès-recherche Dr. André-Robidoux.
Finally, the SC defines and ensures the relevance of the scientific program so that it aligns with the Group’s mission. The selected protocols are made accessible to all members of the Group for the benefit of their patients.
This committee plays a central role within our Group. Composed of research coordinators assigned by their institutions to the studies conducted within the Group, it ensures the smooth operation and cohesion of the consortium. The contribution of those working on the ground has been essential in harmonizing the clinical research practices of the Group’s members and allow us to measure our performance in terms of access to clinical research.
Improving the fight against breast cancer by increasing access to and participation in clinical research studies.
In order to make the text more readable, patients is used in the feminine form since breast cancer mainly affects women.
Website conception and design | Cobbox